Articles |

Comparison of the Maxair Autohaler to Wet Nebulizer in Patients With Acute Asthma FREE TO VIEW

Robert Silverman; Judith Sellers; Sharon Greene; Edith Flaster; Gene Colice
Author and Funding Information

Affiliations: From the Department of Emergency Medicine, Long Island Jewish Medical Center, New York, NY,  From the 3M Pharmaceuticals, St. Paul, MN.,  From the Long Island Campus for the Albert Einstein College of Medicine, Long Island, NY

Robert Silverman, MD, Dept of Emergency Medicine, Long Island Jewish Hospital, New Hyde Park, NY 11040

1998 by the American College of Chest Physicians

Chest. 1998;114(3):766-770. doi:10.1378/chest.114.3.766
Text Size: A A A
Published online


Study objective: Patients with acute asthma often have difficulty using a conventional metered-dose inhaler. The Maxair Autohaler (3M Pharmaceuticals; St. Paul, MN) is a hand-held breath-actuated device developed to help patients coordinate drug administration. The study objective is to compare the efficacy of the Autohaler with inhaled β-agonist administered by wet nebulizer in treating acute asthma exacerbations.

Design: Parallel, randomized, placebo-controlled clinical trial.

Setting: Emergency department (ED) of a university-affiliated hospital.

Participants: Patients aged 18 to 55 years presenting to the ED with acute asthma and an FEV1 40 to 70% on hospital arrival.

Interventions and measurements: Patients were given either six puffs of the Maxair Autohaler (1,200 µg pirbuterol) plus saline solution by nebulizer (active Autohaler group) or six puffs placebo by Autohaler plus 2,500 µg albuterol via nebulizer (active nebulizer group). Treatment was repeated at 30 and 60 min, with clinical evaluation performed before each treatment and again at 120 min. At 120 min, the protocol was completed.

Results: Twenty-four patients were enrolled, with 5 excluded because of protocol violations. Baseline FEV1 percent predicted values for the active Autohaler group were 53% vs 51% for the active nebulizer group (p=not significant [NS]). At time 120 min, values were 66% for Autohaler and 64% for nebulizer (p=NS). The average time to administer Autohaler was 2.9 min, vs 9.1 min for nebulizer. No patient was excluded because of the inability to use the Autohaler device adequately.

Conclusion: In patients with moderate asthma exacerbations, similar improvements in pulmonary function are obtained when β-agonists are given by either the Maxair Autohaler or a wet nebulizer device.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543